Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Sotalol

Klassificering: C

Preparat: Sotacor®, Sotalol 2care4, Sotalol 40 mg I.V. Carino, Sotalol Mylan, Sotalol Orifarm, Sotalol ratiopharm

ATC kod: C07AA07

Substanser: sotalol, sotalolhydroklorid

Sammanfattning

Många antiarytmika förlänger repolarisationstiden vilket syns på EKG som en förlängning av QT-intervallet. Detta ökar risken för allvarlig kammartakykardi av typen Torsade de pointes. Kvinnor har större risk än män att få Torsade de pointes vid behandling med antiarytmika. Förekomsten av torsade de pointes verkar inte vara relaterat till någon bestämd serumkoncentrationsnivå.

Vid behandling med sotalol bör den ökade risken för allvarlig kammartakykardi hos kvinnor beaktas.

Additional information

Pharmacokinetics and dosing

An open-label randomized parallel study (12 men, 12 women) investigated the pharmacokinetics of intravenous doses of d-sotalol up to 3.0 mg/kg. Volume of distribution at steady-state (Vdss) was found to be 16% lower in women than men [1]. The authors suggests this small difference to not be clinically important. For other pharmacokinetic parameters, there were no differences observed between men and women [1]. Despite the small pharmacokinetic differences of sotalol, the clinical studies have shown effect with similar doses in men and women and no sex differentiation in dosing has been suggested [2].

Effects

In a randomized double-blind trial (234 men, 66 women), the efficacy of oral low-dose sotalol was compared with placebo in the prophylactic treatment of supraventricular tachyarrhythmia (SVT) shortly after coronary artery bypass grafting. Male patients had a less protection by sotalol and therefore developed more postoperative SVTs than women (risk ratio 1.7) [3].

Adverse effects

Sex differences in the proarrhythmic potential of QT-prolonging drugs are well documented. Women have a greater risk than men of developing dangerous ventricular tachycardias, Torsade de pointes (TdP), when given drugs prolonging repolarization [4]. A meta-analysis report that female sex is a risk factor for sotalol-induced TdP. Of the 332 cases of TdP in this meta-analysis, 70% were women [5]. Thus, the occurrence of TdP was independent of dosage and does not appear to be related to any critical serum drug level. It is suggested that this findings could be explained by a female predisposition to prolonged cardiac repolarization. Even in the normal population, women have a longer average QT-interval than men [5, 6]. Also in further analysis of a database including more than 3000 patients given sotalol for treatment of atrial or ventricular arrhythmias, women were found to be at increased risk of developing TdP when taking the drug; 4.1% of the women vs. 1.0% of the men had TdP [7]

The mortality risk of d-sotalol in patients after myocardial infarction with left ventricular dysfunction was investigated in the SWORD trial (2679 men, 442 women). Men and women were at a similar risk of death in the overall SWORD population. Relative to placebo, d-sotalol was associated with a 4.7-fold increased risk of death in women and a 1.4-fold increase in men. This difference was not significant but the confidence intervals were large due to few women in comparison with men in the trial [8].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Fler män än kvinnor hämtade ut tabletter innehållande sotalol (ATC-kod C07AA07) på recept i Sverige år 2015, totalt 5 369 män och 4 378 kvinnor. Det motsvarar 1,1 respektive 0,9 personer per tusen invånare. Andelen som hämtat ut läkemedel ökade med stigande ålder hos båda könen. I genomsnitt var tabletter innehållande sotalol 1,8 gånger vanligare hos män [9].

Uppdaterat: 2019-02-26

Litteratursökningsdatum: 2014-02-12

Referenser

  1. Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J Clin Pharmacol. 1997;37:799-809. PubMed
  2. Sotacor (sotalol). Summary of Product Charateristics. Medical Products Agency Sweden; 2013.
  3. Suttorp MJ, Kingma JH, Peels HO, Koomen EM, Tijssen JG, van Hemel NM et al. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol. 1991;68:1163-9. PubMed
  4. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D. PubMed
  5. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-7. PubMed
  6. Yarnoz MJ, Curtis AB. More reasons why men and women are not the same (gender differences in electrophysiology and arrhythmias). Am J Cardiol. 2008;101:1291-6. PubMed
  7. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94:2535-41. PubMed
  8. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?. Am J Cardiol. 1998;81:869-76. PubMed
  9. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Författare: Linnéa Karlsson Lind, Desirée Loikas

Faktagranskat av: Mia von Euler

Godkänt av: Karin Schenck-Gustafsson